Biobase calls itself the agentic system for clinical data. In practice it is a brokerage: health systems, labs and biobanks put their biospecimens, whole-slide images and the clinical metadata attached to them to work through Biobase, and pharma, biotech and AI teams buy research-ready access on the other side. The company normalizes and indexes data arriving in incompatible formats (EHR, LIMS, HL7, FHIR, pathology slides, genomics), runs a federated model where data stays with the institution that holds it, and builds HIPAA-aligned de-identification, lineage and audit trails into the pipeline. On top of that supply chain it runs AI agents, both for customers (cohort discovery, natural language querying) and against its own operations (lead follow-up, briefings, monitoring).
The company is young and small: headquartered in San Diego, California, with a team of about a dozen people as of October 2026 per its LinkedIn page. The founding team comes from pathology AI and healthcare data companies including Paige, Tempus, Arterys, Danaher and PictorLabs, and it says it is already working with health systems, labs and technology partners, including a strategic relationship with BJC Health, one of the largest academic health systems in the US.